Slide 1: Exchange filing cover letter
5th August, 2021 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scri
Slide 2: Investor Presentation Q1FY22
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q1FY22 August 5, 2021
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: Continued progress across our key strategic priorities
Continued progress across our key strategic priorities CLICK TO EDIT MASTER TITLE STYLE South Africa & International Global lung leadership & US One India Markets Generics ❖ Strong traction across branded ❖ Growth 1.5 times of SA private ❖ Strong scale-up in US Direct to prescription, trade generics
Slide 5: Strong demand-led momentum in core therapies across branded markets
Strong demand-led momentum in core therapies across branded markets CLICKand continued TO EDIT MASTERrespiratory TITLE STYLE unlocking in the US drive Q1FY22 performance Overall Revenue One India Trade Consumer Prescription Generics Health Overall revenue 68% Continued market beating growth over Str
Slide 6: Strong capital structure and robust free cash flow generation continues
Strong capital structure and robust free cash flow generation continues CLICK TO EDIT MASTERin FY22 TITLE STYLE Net Cash1 Net Cash / Equity Cash Balances2 (INR Cr) (INR Cr) 0.15 2,964 4,895 0.10 3,676 1,921 Mar'21 Jun'21 Mar'21 Jun'21 Mar'21 Jun'21 ▪ Continued governance on cash and liquidity manage
Slide 7: Financial Performance – Q1FY22
Financial Performance – Q1FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,504 Cr 27% YoY EBITDA INR 1,346 Cr │ 24.5% 28% YoY Q1 FY22 (Consolidated) Revenue1 Break-up Actuals Others, 1% vs Q1 FY 21 (Rs Cr) API, 5% International Total Revenue from Markets, 5,504 27% Operations 11% EBITDA 1,346 28
Slide 8: One India (Rx + Gx+ CHL): Consistent execution driving growth across businesses
One India (Rx + Gx+ CHL1): Consistent execution driving growth across CLICK TO EDITbusinesses MASTER TITLEinSTYLE India Key Business Highlights One India Branded prescription business ❖ Strong volume traction in core therapy portfolio Rs. Cr Q1 Y-o-Y ❖ Acute and respiratory nebulization recovered we
Slide 9: Global consumer health franchise gaining traction
Global consumer health franchise gaining traction CLICK TO EDIT MASTER TITLE STYLE 6.9% contribution to overall revenues in Q1FY22; Improving consumer health outcomes Anchor consumer brands in India1 Anchor consumer brands in South Africa 3% #1 #1 31% Pain Relief Category (Q1FY22 NRT* (Q1FY22 YoY gr
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE Key Business Highlights SAGA: 13% Y-o-Y South Africa ❖ Continued market beating growth in South Africa (SA) $ Mn private business SA Private market Q1 Y-o-Y ❖ Double digit growth and market share gain in
Slide 11: North America: Continued traction in core formulation portfolio
North America: Continued traction in core formulation portfolio CLICK TO EDIT MASTER TITLE STYLE Key Business Highlights North America US Generics ramp-up continues ❖ Continued market share expansion in overall Albuterol market $ Mn ❖ New approval: Arformoterol Tartrate Inhalation Solution 15 mcg /
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th June 2021)
ANDA & NDA1 Portfolio & Pipeline (As on 30th June 2021) CLICK TO EDIT MASTER TITLE STYLE Total ANDAs 171 18 74 263 & NDAs 22 58 9 4 21 82 8 3 1 9 41 5 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet product AN
Slide 13: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn $ Mn Q1 Y-o-Y Q1 Y-o-Y 92 -14% 79 41 69% 24 Q1FY21 Q1FY22 Q1FY21 Q1FY22 Key Business Highlights Key Business Highlights ❖ Sales momentum supported by strong ❖ Emerging markets business impacted by customer
Slide 14: Our FY22 priorities include
Our FY22 priorities include CLICK TO EDIT MASTER TITLE STYLE Ensuring Covid portfolio availability and maximize patients reach Maintain market beating growth in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise Expanding lung leadership glo
Slide 15: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com